Raymond James started coverage on shares of Ardelyx (NASDAQ:ARDX – Free Report) in a research note issued to investors on Monday, Marketbeat.com reports. The firm issued a strong-buy rating and a $12.00 price objective on the biopharmaceutical company’s stock. A number of other equities research analysts have also recently issued reports on the stock. StockNews.com […]